<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00065156</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MDS-003</org_study_id>
    <nct_id>NCT00065156</nct_id>
    <nct_alias>NCT00074126</nct_alias>
  </id_info>
  <brief_title>Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality</brief_title>
  <official_title>A Multicenter, Single-arm, Open-label Study of the Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion-dependent Subjects With Myelodysplastic Syndromes Associated With a Del(5q) Cytogenetic Abnormality.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, single-arm, open-label study of oral lenalidomide monotherapy
      administered to red blood cell (RBC) transfusion-dependent subjects with low- or
      intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del (5q31-33)
      cytogenetic abnormality. Screening procedures will take place within 28 days of the first day
      of lenalidomide treatment. Subjects will receive lenalidomide in 28-day cycles for up to 6
      cycles, or until bone marrow disease progression or progression/relapse following erythroid
      hematologic improvement is documented. Study visits will occur every cycle (every 28 days)
      and laboratory monitoring to assess hematological parameters will occur every 14 days. Safety
      and efficacy assessments to be performed during the study are outlined in the Schedule of
      Study Assessments.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive &quot;rolling&quot; 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Adverse Experiences</measure>
    <time_frame>Up to 2 Years</time_frame>
    <description>Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.
The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With a &gt;= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study</measure>
    <time_frame>Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)</time_frame>
    <description>A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Transfusion Independence</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive &quot;rolling&quot; 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive &quot;rolling&quot; 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimate for Duration of Transfusion Independence Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders</measure>
    <time_frame>Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)</time_frame>
    <description>The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Counts of Cytogenetic Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least
1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Counts of Platelet Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Major platelet response: participants with a minimum pretreatment platelet of &lt;100,000/mm^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence.
Minor platelet response: participants with a minimum pretreatment platelet of &lt;100,000/mm^3, a ≥ 50% increase in platelet count with a net increase &gt;10,000/mm^3 for a consecutive 56-day period in the absence of platelet transfusions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Counts of Absolute Neutrophil Count (ANC) Response</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Major neutrophil response: participants with a minimum pretreatment ANC concentration of &lt; 1500/mm^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of
≥ 500/mm^3, whichever was greater (at least to be ≥ 500/mm^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of &lt; 1500/mm^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Complete or Partial Bone Marrow Improvement</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Bone Marrow Progression</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics):
Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB).
Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">148</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lenalidomide</intervention_name>
    <description>10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>CC-5013</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must understand and voluntarily sign an informed consent form

          -  Age 18 years or older at the time of signing the informed consent

          -  Must be able to adhere to the study visit schedule and other protocol requirements.

          -  Diagnosis of low or intermediate-1-risk International Prognostic Scoring System (IPSS)
             Myelodysplastic Syndromes (MDS) without an abnormality of chromosome 5 involving a
             deletion between bands q31 and q33.

          -  Red blood cell (RBC) transfusion-dependent anemia defined as having received greater
             than or equal to 2 units of RBCs within 8 weeks of the first day of study drug
             treatment.

          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.

          -  Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy
             test within 7 days of starting study drug.

          -  Sexually active WCBP must agree to use adequate contraceptive methods (oral,
             injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine
             device; barrier contraceptive with spermicide; or vasectomized partner) while on study
             drug.

          -  WCBP must agree to have pregnancy tests every 4 weeks while on study drug.

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Prior therapy with lenalidomide.

          -  An abnormality of chromosome 5 involving a deletion between bands q31 and q33.

          -  Lab Abnormality: Absolute neutrophil count (ANC) &lt;500 cell/mm^3 (0.5*10^9/L)

          -  Lab Abnormality: Platelet count &lt;50,000/mm^3 (50*10^9/L)

          -  Lab Abnormality: Serum creatinine &gt;2.5 mg/dL (221 mmol/L)

          -  Lab Abnormality: Serum total bilirubin &gt;2.0 mg/dL (34 mmol/L)

          -  Prior greater than or equal to grade 3 National Cancer Institute (NCI) Common Toxicity
             Criteria (CTC) allergic reaction/hypersensitivity to thalidomide.

          -  Clinically significant anemia due to factors such as iron, B12 or folate deficiencies,
             autoimmune or hereditary hemolysis or gastrointestinal bleeding

          -  If a marrow aspirate is not evaluable for storage iron, transferrin saturation must be
             &gt; 20% and serum ferritin not less than 50 ng/mL

          -  Use of hematopoietic growth factors within 7 days of the first day of study drug
             treatment.

          -  Prior greater than or equal to grade 3 NCI CTC rash or any desquamation (blistering)
             while taking thalidomide.

          -  Chronic use (&gt;2 weeks) of greater than physiologic doses of a corticosteroid agent
             (dose equivalent to &gt;10 mg/day of prednisone) within 28 days of the first day of study
             drug treatment.

          -  Use of experimental or standard drugs (i.e. chemotherapeutic, immunosuppressive, and
             cytoprotective agents) for the treatment of MDS within 28 days of the first day of
             study drug treatment.

          -  Prior history of malignancy other than MDS (except basal cell or squamous cell
             carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been
             free of disease for greater than or equal to 3 years.

          -  Use of any other experimental therapy within 28 days of the first day of study drug
             treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan F List, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724-5024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Desert Hematology &amp; Oncology Medical Group</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer &amp; Blood Disease Center</name>
      <address>
        <city>Lecanto</city>
        <state>Florida</state>
        <zip>34461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comp Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612-9497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology - Wellstar Cancer Research</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush-Presbyterian- St. Luke's Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Cancer Research Group</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8963</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University School of Medicine</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2097</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198-7680</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Hospital-Cornell</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-0034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021-6007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester- James P. Wilmot Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27157-1082</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Northwest Region</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Pennsylvania Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-4417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Johannes Hospital</name>
      <address>
        <city>Duisburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R; Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006 Oct 5;355(14):1456-65.</citation>
    <PMID>17021321</PMID>
  </results_reference>
  <results_reference>
    <citation>A.F. List, et.al. Results of the MDS-002 and -003 international phase II studies evaluating lenalidomide (CC-5013; Revlimid) in the treatment of transfusion-dependent (TD) patients with myelodysplastic syndrome (MDS). European Hematology Association 10th Conference June 2-5, 2005 Abstract #0772</citation>
  </results_reference>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2003</study_first_submitted>
  <study_first_submitted_qc>July 17, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2003</study_first_posted>
  <results_first_submitted>August 31, 2009</results_first_submitted>
  <results_first_submitted_qc>May 10, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 9, 2010</results_first_posted>
  <last_update_submitted>October 5, 2011</last_update_submitted>
  <last_update_submitted_qc>October 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MDS</keyword>
  <keyword>CC-5013</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Celgene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Chromosome Aberrations</mesh_term>
    <mesh_term>Chromosome Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lenalidomide</title>
          <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intent to Treat Population</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24">24 patients rolled over to free drug due to sponsor closure of study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closed by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Loss of Response</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Secondary Malign Disease</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lenalidomide</title>
          <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.0" spread="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Myelodysplastic Syndrome (MDS)</title>
          <description>Time from diagnosis of MDS until study start.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="3.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Participants with 5q(-) (31-33) Chromosomal Abnormality</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Prognostic Scoring System (IPSS) Score</title>
          <description>The international prognostic scoring system (IPSS) is a standard for risk assessment in primary myelodysplastic syndromes (MDS) that categorizes prognoses taking into account cytogenetics, cytopenias, blasts and blood counts. The IPSS prognostic subgroups consist of low-, intermediate-1-, intermediate-2-, and high-risk groups. The scale is 0-3.5 at 0.5 increments. Scores of 0=Low; 0.5-1.0=Int-1; 1.5-2.0=Int-2; 2.5-3.5=High risk which corresponds to poorer prognosis. The assessment was performed by the Central Reviewer.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Low (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate-1 (0.5 to 1.0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate-2 (1.5 to 2.0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High (&gt;=2.5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing (unable to assign)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>French-American-British (FAB) Classification</title>
          <description>FAB is a classification system for five (5) subtypes of myelodysplastic syndrome that are distinguished by the percentage of myeloblasts, presence or absence of ringed sideroblasts or a monocytosis. Classification was made by the Central Reviewer.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Refractory anemia (RA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refractory anemia with ringed sideroblasts (RARS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refractory anemia with excess blasts (RAEB)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic myelomonocytic leukemia (CMML)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute leukemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unable to classify</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cytogenetic Complexity</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Isolated 5q</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate (5q + 1 abnormality)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complex</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) Performance Status</title>
          <description>ECOG indicates a person's ability to perform life's functions on a scale of 0-5:
0= fully active and no restrictions
restricted but ambulatory and capable of light work
ambulatory and capable of self-care but unable to work
3-4= increasingly restricted
5= dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence</title>
        <description>Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.</description>
        <time_frame>Up to 2 years</time_frame>
        <population>Modified Intent to Treat (MITT)
diagnosis of low- or int-1-risk MDS associated with a del(5q) cytogenetic abnormality based on central hematologic and cytogenetic reviewers confirmation
received ≥2 transfusions in each of the 8-week periods during the 16 week pre-treatment period
received ≥1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence</title>
          <description>Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.</description>
          <population>Modified Intent to Treat (MITT)
diagnosis of low- or int-1-risk MDS associated with a del(5q) cytogenetic abnormality based on central hematologic and cytogenetic reviewers confirmation
received ≥2 transfusions in each of the 8-week periods during the 16 week pre-treatment period
received ≥1 dose of study drug</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Adverse Experiences</title>
        <description>Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.
The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.</description>
        <time_frame>Up to 2 Years</time_frame>
        <population>Safety population included all participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Adverse Experiences</title>
          <description>Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator.
The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.</description>
          <population>Safety population included all participants who received at least one dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one NCI CTC grade 3-4 AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one NCI CTC grade 3-4 AE related to drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one serious AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At least one serious AE related to study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to dose reduction or interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With a &gt;= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study</title>
        <description>A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).</description>
        <time_frame>Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)</time_frame>
        <population>Modified Intent to Treat (MITT)
diagnosis of low- or int-1-risk MDS associated with a del(5q) cytogenetic abnormality based on central hematologic and cytogenetic reviewers confirmation
received ≥2 transfusions in each of the 8-week periods during the 16 week pre-treatment period
received ≥1 dose of study drug</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a &gt;= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study</title>
          <description>A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).</description>
          <population>Modified Intent to Treat (MITT)
diagnosis of low- or int-1-risk MDS associated with a del(5q) cytogenetic abnormality based on central hematologic and cytogenetic reviewers confirmation
received ≥2 transfusions in each of the 8-week periods during the 16 week pre-treatment period
received ≥1 dose of study drug</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Transfusion Independence</title>
        <description>Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Modified intent to treat population who achieved transfusion independence</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Transfusion Independence</title>
          <description>Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.</description>
          <population>Modified intent to treat population who achieved transfusion independence</population>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2" spread="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study</title>
        <description>Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Modified intent to treat population who achieved transfusion independence</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study</title>
          <description>Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive “rolling” 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.</description>
          <population>Modified intent to treat population who achieved transfusion independence</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Relapsed (had a transfusion after response)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintained transfusion independence</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimate for Duration of Transfusion Independence Response</title>
        <description>Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Modified intent to treat population who achieved transfusion independence</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimate for Duration of Transfusion Independence Response</title>
          <description>Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.</description>
          <population>Modified intent to treat population who achieved transfusion independence</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.0" lower_limit="52.9" upper_limit="191.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders</title>
        <description>The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.</description>
        <time_frame>Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)</time_frame>
        <population>Modified intent to treat population who achieved transfusion independence</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders</title>
          <description>The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.</description>
          <population>Modified intent to treat population who achieved transfusion independence</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Counts of Cytogenetic Response</title>
        <description>Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least
1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Evaluable participants from the modified intent to treat population. Evaluable participants had ≥ 20 metaphases analyzed at baseline during the 56-day period immediately preceding the first day of study drug intake and ≥ 20 metaphases analyzed at least once at postbaseline visits.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Counts of Cytogenetic Response</title>
          <description>Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least
1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.</description>
          <population>Evaluable participants from the modified intent to treat population. Evaluable participants had ≥ 20 metaphases analyzed at baseline during the 56-day period immediately preceding the first day of study drug intake and ≥ 20 metaphases analyzed at least once at postbaseline visits.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Counts of Platelet Response</title>
        <description>Major platelet response: participants with a minimum pretreatment platelet of &lt;100,000/mm^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence.
Minor platelet response: participants with a minimum pretreatment platelet of &lt;100,000/mm^3, a ≥ 50% increase in platelet count with a net increase &gt;10,000/mm^3 for a consecutive 56-day period in the absence of platelet transfusions.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Evaluable participants from the modified intent to treat population. Participants must have a baseline platelet count &lt;100 * 10^9/L to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Counts of Platelet Response</title>
          <description>Major platelet response: participants with a minimum pretreatment platelet of &lt;100,000/mm^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence.
Minor platelet response: participants with a minimum pretreatment platelet of &lt;100,000/mm^3, a ≥ 50% increase in platelet count with a net increase &gt;10,000/mm^3 for a consecutive 56-day period in the absence of platelet transfusions.</description>
          <population>Evaluable participants from the modified intent to treat population. Participants must have a baseline platelet count &lt;100 * 10^9/L to be included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Counts of Absolute Neutrophil Count (ANC) Response</title>
        <description>Major neutrophil response: participants with a minimum pretreatment ANC concentration of &lt; 1500/mm^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of
≥ 500/mm^3, whichever was greater (at least to be ≥ 500/mm^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of &lt; 1500/mm^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Evaluable participants from the modified intent to treat population. Evaluable participants are required to have a baseline absolute neutrophil count (ANC) &lt;1 * 10^9/L.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Counts of Absolute Neutrophil Count (ANC) Response</title>
          <description>Major neutrophil response: participants with a minimum pretreatment ANC concentration of &lt; 1500/mm^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of
≥ 500/mm^3, whichever was greater (at least to be ≥ 500/mm^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of &lt; 1500/mm^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.</description>
          <population>Evaluable participants from the modified intent to treat population. Evaluable participants are required to have a baseline absolute neutrophil count (ANC) &lt;1 * 10^9/L.</population>
          <units>participant</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Major</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Complete or Partial Bone Marrow Improvement</title>
        <description>Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.</description>
        <time_frame>up to 2 years</time_frame>
        <population>Modified intent to treat population of participants with adequate bone marrow aspirate at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Complete or Partial Bone Marrow Improvement</title>
          <description>Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.</description>
          <population>Modified intent to treat population of participants with adequate bone marrow aspirate at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete bone marrow improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial bone marrow improvement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Bone Marrow Progression</title>
        <description>Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics):
Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB).
Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).</description>
        <time_frame>up to 2 years</time_frame>
        <population>Modified intent to treat population of participants with adequate bone marrow aspirate at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Lenalidomide</title>
            <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Bone Marrow Progression</title>
          <description>Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics):
Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB).
Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).</description>
          <population>Modified intent to treat population of participants with adequate bone marrow aspirate at baseline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RA/RARS to RAEB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RA/RARS/RAEB/CMML to AML</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lenalidomide</title>
          <description>The protocol initially employed a syncopated dosage regimen in which 10 mg of lenalidomide was taken orally once daily on Days 1 to 21 of a 28-day cycle, but was subsequently amended to employ a continuous dosage regimen in which 10 mg of lenalidomide was taken without a planned rest period. Participants who initially began therapy on the syncopated regimen and who did not experience dose-limiting adverse events (AEs) were allowed to switch to the continuous regimen.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardiac Failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diastolic Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastroenteritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Colitis Ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastritis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Irritable Bowel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Oesophageal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Perirectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Intermittent Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sepsis NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bronchitis Acute NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Central Line Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Clostridial Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Enterobacter Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Groin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Klebsiella Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Post Procedural Site Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinusitis Acute NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vaginosis Fungal NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Comminuted Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Overdose NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Troponin I Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthrlagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Localised Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Osteolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Leukaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Acute Myeloid Leukaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>B-Cell Lymphoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Carcinoid Tumour of the Small Bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Multiple Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Refractory Anaemia with Excess Blasts in Transformation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Thymoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Convulsions NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dementia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypertensive Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Migraine NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Senile Dementia NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dyspnoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pneumonitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Asthma NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Airways Disease Exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lung Infiltration NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Acute Febrile Neutrophilic Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dermatitis Medicamentosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="93" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anaemia NOS</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Leukopenia NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Loose Stools</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Oedema NOS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Appetite Decreased NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Muscle Cramp</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain in Limb</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Peripheral Swelling</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain in Foot</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Peripheral Neuropathy NOS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Peripheral Sensory Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dyspnoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bronchitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rhinitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sweating Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Skin Lesions NOS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension NOS</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Unless approved by Celgene, single center data will not be published before multicenter data, unless more than 1 year has elapsed since completion of the Study. Thereafter, Investigator may publish single center data provided that Investigator shall: i) provide a copy of the publication to Celgene at least 60 days in advance of submission for publication; ii) delete Celgene Confidential Information and; iii) delay submission up to 90 additional days to permit intellectual property filings.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Associate Director, Clinical Trials Disclosure</name_or_title>
      <organization>Celgene Corporation</organization>
      <phone>1-888-260-1599</phone>
      <email>clinicaltrialdisclosure@celgene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

